Managed Care

 

Economic Analysis of Oral and Topical Therapies For Onychomycosis of the Toenails and Fingernails

MANAGED CARE March 2003. © MediMedia USA
Peer-Reviewed

Economic Analysis of Oral and Topical Therapies For Onychomycosis of the Toenails and Fingernails

Julian Casciano
The Analytica Group, New York, N.Y.
Karine Amaya, PhD
The Analytica Group, New York, N.Y.
John Doyle, MPH
The Analytica Group, New York, N.Y.
Steve Arikian, MD
The Analytica Group, New York, N.Y.; Columbia University, New York, N.Y.
Neil Shear, MD
Sunnybrook Medical Center, Toronto, Canada
MANAGED CARE March 2003. ©MediMedia USA

Julian Casciano

The Analytica Group, New York, N.Y.

Karine Amaya, PhD

The Analytica Group, New York, N.Y.

John Doyle, MPH

The Analytica Group, New York, N.Y.

Steve Arikian, MD

The Analytica Group, New York, N.Y.; Columbia University, New York, N.Y.

Neil Shear, MD

Sunnybrook Medical Center, Toronto, Canada

Marc Haspel, DPM

Podiatric Medicine and Surgery, Clifton, N.J.

Kristijan Kahler

Novartis Pharmaceuticals Corp., East Hanover, N.J.

ABSTRACT

Objective: Several antifungal agents are indicated for onychomycosis, a fungal infection of the toenails and fingernails. These agents differ in their dosing regimen, efficacy, adverse events profile, potential for drug interaction, and cost. We conducted a pharmacoeconomic analysis of oral and topical therapies for onychomycosis from the perspective of a hypothetical managed care payer to determine the most cost-effective agent.

Design: A decision analytic model was developed to evaluate the pharmacoeconomic profiles of itraconazole–continuous (Sporanox, Janssen Pharmaceutica), itraconazole–pulse (Sporanox, Janssen Pharmaceutica), terbinafine (Lamisil, Novartis Pharmaceuticals), and ciclopirox (Penlac, Dermik Laboratories) in the treatment of fingernail and toenail onychomycosis.

Methodology: We conducted a meta-analysis of the available literature to populate the decision analytic model with clinical point estimates for success, failure, and relapse. A panel of expert dermatologists defined resources consumed during the onychomycosis treatment process. These resources were then assigned values, using publicly available data sources, to reflect the U.S. managed care perspective. These clinical and economic data elements were integrated in the decision analytic model to arrive at the expected cost of treatment for each drug. Additionally, incremental cost-effectiveness was calculated for treatment success and disease-free days achieved by each therapy. Finally, a policy-level analysis of the budgetary impact of using the therapies for onychomycosis in a managed care setting was conducted.

Results: The meta-analysis demonstrated terbinafine to be the therapeutic alternative with the highest success rate for both fingernails (96.55 percent) and toenails (81.15 percent). Terbinafine also had the lowest relapse rate (6.42 percent) and the highest number of disease-free days for both fingernails and toenails. Subsequently, in terms of cost-effectiveness, terbinafine dominated all other comparators for fingernails and toenails.

Conclusions: Based on the patient-level analysis, we concluded that terbinafine is the most cost-effective therapy in the treatment of onychomycosis from a managed care perspective. Furthermore, at the policy level, increased utilization of terbinafine among onychomycosis patients is likely to reduce the managed care organizations' per member per month cost.

Key words: onychomycosis, itraconazole, Sporanox, terbinafine, Lamisil, ciclopirox, Penlac, pharmacoeconomics, meta-analysis

Author correspondence:

Steve Arikian, MD
The Analytica Group
475 Park Ave. South–7th Floor
New York, NY 10016
Phone: (212)-686-4100
Fax: (212)-686-8601
Email: sarikian@theanalyticagroup.com

This paper has undergone peer review by appropriate members of Managed Care's Editorial Advisory Board.

Meetings

4th Partnering With ACOs Summit Los Angeles, CA October 27–28, 2014
PCMH & Shared Savings ACO Leadership Summit Nashville, TN November 3–4, 2014
2014 Annual HEDIS® and Star Ratings Symposium Nashville, TN November 3–4, 2014
Medicare Risk Adjustment, Revenue Management, & Star Ratings Fort Lauderdale, FL November 12–14, 2014
World Orphan Drug Congress Europe 2014 Brussels, Belgium November 12–14, 2014
Healthcare Chief Medical Officer Forum Alexandria, VA November 13–14, 2014
Home Care Leadership Summit Atlanta, GA November 17–18, 2014
HealthIMPACT Southeast Tampa, FL January 23, 2015